About the smallcase

Overall Pharma sector was under pressure in the past 2 years. However, we believe progressive improvement in business outlook, primarily driven by healthy growth in domestic business, normalization of price erosion in US business coupled with big ticket launches for selected companies, and favorable currency movement.

Live Performance

Unlock all metrics

Login to see the
live performance and return

Understand smallcase costs and returns

Understand smallcase costs and returns